Canaccord analyst Richard Close lowered the firm’s price target on Doximity to $30 from $40 and keeps a Buy rating on the shares. The firm lowered their estimates following the early August 1Q report that surprised to the upside, delivering 20% growth, but disappointed with a downward guidance revision due to slowing pharma digital marketing spend that puts the FY’24 revenue growth range at 6-7%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DOCS: